Eli Lilly (LLY) Revenue & Earnings History | Quarter Chart
Income Statement▲
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Cash Flow Statement▲
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Balance Sheet▲
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Key Metrics▼
Eli Lilly (LLY) quarterly earnings & revenue
Eli Lilly (LLY) is the #15 largest public company in the world by market capitalization, operating in the Drug Manufacturers - General industry.
Eli Lilly (LLY) reported revenue of $22.97B for Q2 2026, up 47.7% year-over-year, with net income of $7.09B and diluted EPS of $7.94.
Over the last four reported quarters, Eli Lilly generated $79.67B in revenue and $26.71B in net income.
Eli Lilly's next earnings report is scheduled for October 29, 2026 before market open (provider scheduled date). Check the earnings calendar to see all companies reporting this week.
Eli Lilly quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q2 2026 | $22.97B | +47.7% | $7.09B | $7.94 |
| Q1 2026 | $19.80B | +55.5% | $7.40B | $8.26 |
| Q4 2025 | $19.29B | +42.6% | $6.64B | $7.39 |
| Q3 2025 | $17.60B | +53.9% | $5.58B | $6.21 |
Compare with other Healthcare companies: Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)